CollPlant (NASDAQ: CLGN),a regenerative and aesthetics medicine company, today announced the appointment of Hugh Evans to its Board of Directors, increasing the board to six independent members.
U.S.-based Mr. Evans brings extensive board, 3D printing technology, and investment experience to CollPlant. He currently serves on the boards of four manufacturing technology companies including Factory Four, ZVerse, 3DM, and is also a Non-Executive Chairman of Culinary Printworks. He was formerly a board member of AquaVenture Holdings, which was acquired by Culligan International.
Mr. Evans served as Senior Vice President of Corporate Development & Digitization at 3D Systems Corporation, a leading 3D printing company, where he led M&A, venture capital investments, joint ventures, and technology licensing. Previously, he served as a portfolio manager at T. Rowe Price Associates in Baltimore, Maryland for over 20 years.
“Hugh brings significant insights and experience that will be invaluable to CollPlant as we continue to execute our strategic vision. His achievements as a senior executive and board member, complemented by his notable expertise in the 3D printing industry will undoubtedly serve us well as we continue to grow, ” said Yehiel Tal, CollPlant Chief Executive Officer. “Hugh is an excellent addition to our board of directors and will play an integral role in our mission to help people live longer and better through our innovative collagen technology.”
“I’m thrilled to join CollPlant’s board at a pivotal time in the Company’s mission to revolutionize the fields of regenerative and aesthetic medicine via its rhCollagen technology platform,” said Mr. Evans. “I look forward to contributing from my experience in additive manufacturing to support CollPlant in pioneering novel solutions for patients around the world.”
CollPlant’s Chairman, Dr. Roger J. Pomerantz commented, “Hugh has a deep understanding and appreciation of CollPlant’s technology and how it can be transformative in advancing the 3D bioprinting field. We are very pleased to welcome him to the board and look forward to his guidance and support.”
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company’s products are based on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information, visit http://www.collplant.com.
Safe Harbor Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant’s objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the impact of the COVID-19 pandemic; the Company’s expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company’s ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company’s rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships and other corporate collaborations; the Company’s reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company’s ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company’s strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading “Risk Factors” included in CollPlant’s most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
